515
Participants
Start Date
March 8, 2019
Primary Completion Date
June 8, 2022
Study Completion Date
June 8, 2022
18-month regimen containing 6 anti-TB drugs
Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
Beijing Chest Hospital, Beijing
The 8th Medical Center of Chinese Pla General Hospital, Beijing
Changchun Infectious Disease Hospital, Changchun
Hunan Institute For Tuberculosis Control, Changsha
Public Health Clinical Center of Chengdu, Chengdu
Shenzhen Third Peple's Hospital, Guangzhou
Guangzhou Chest Hospital, Guanzhou
The Affiliated Hospital of Guizhou Medical University, Guiyang
Infectious Disease Prevention Hospital in Heilongjiang Province, Harbin
Anhui Chest Hospital, Hefei
The Fourth People's Hospital of Inner Mongolia Autonomous region, Hohhot
Shandong Provincial Chest Hospital, Jinan
Shanghai Pulmonary Hospital, Shanghai
Shenyang Chest Hospital, Shenyang
Tianjin Haihe Hospital, Tianjin
Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Ürümqi
The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an
Xi'an Chest Hospital, Xi'an
The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan
The Infectious Disease Hospital of Wangkai Zaozhuang, Zaozhuang
Beijing Chest Hospital
OTHER